The rationale for platelet-to-lymphocyte ratio (PLR) in chronic lymphocytic leukemia (CLL) is that both the platelet and lymphocyte counts are affected by the CLL pathogenesis and could influence treatment decision-making. Methods: Demographic and clinical data of CLL patients diagnosed at our institution between 1989 and 2013 were collected. Cox regression models were used to evaluate the role of PLR in the duration of watchful waiting, postdiagnosis survival and postchemotherapy survival. Results: The data of 100 patients with CLL were reviewed for this study. The PLR correlated only to watchful waiting in the univariable analysis (Hazard ratio = 0.48 [0.32-0.73]; p = 0.018). In the multivariable analysis, the duration of watchful waiting was determined by Binet staging and lymphocyte count (p < 0.001). The postdiagnosis survival was determined by age (p = 0.002) and lymphocyte count (p = 0.010). Conclusion: The PLR did not seem to act as a prognostic biomarker for CLL.
Platelet count/mm 3 -median (range) 199,500 (14,000-458,000)
Platelet to lymphocyte ratio -median (range) 11.27 (0. 14-159.77) cytometry signature characterized by CD5 + , CD19 + , CD23 + , CD20 (dim) and surface immunoglobulin (dim). The small lymphocytic lymphoma patients did not require a lymphocytosis above 5 × 10 9 /l with at least 50% B-lymphocytes [6] . The records were also reviewed for epidemiologic data and clinical presentation. The laboratory tests at diagnosis were collected, before any treatment, including the lymphocyte count (number/mm 3 ) and platelet count (number/mm 3 ). We calculated the PLR by dividing the absolute count of platelets to that of lymphocytes at diagnosis (when both expressed in number/mm 3 ). All patients were classified according to the Binet system at diagnosis. For all patients, three survival end points were defined. First, duration of watchful waiting was defined as the time from diagnosis until the start of chemotherapy or death. Second, postdiagnosis survival (or overall survival [OS]) was defined as the duration from diagnosis until death. Third, postchemotherapy survival was defined as the duration from the start of chemotherapy until death. All three end points were reported in number of days. Patients who were lost to follow-up or who did not suffer any of the events for a given end point at last follow-up were censored for that end point.
Continuous variables were summarized by their medians and ranges. Categorical variables were summarized by number and percentage of patients within each category. SPSS Statistics version 20.0 (IBM Corporation, NY, USA) and XlStat version 2017.1 (Addinsoft, Paris, France) were used for statistical analysis. All continuous variables were analyzed as such and not categorized. Univariable Cox regression models were computed while considering duration of watchful waiting, postdiagnosis survival and postchemotherapy survival as dependent variables, and demographic, laboratory and disease characteristics as independent variables. Multivariable stepwise Cox regression models were subsequently computed with all independent variables included. Effect sizes were reported as hazard ratios (HR) for univariable tests and adjusted hazard ratios (HRa) for multivariable tests, with their 95% CIs. All tests were two-tailed and considered statistically significant for p < 0.05.
Results
A total of 100 CLL patients with a median age of 64 years (range 36-89) were included in this study and their characteristics are summarized in Table 1 . At diagnosis, the median absolute count of lymphocytes was 18,500/mm 3 (range 1596-290,000/mm 3 ) and platelets 199,500/mm 3 (range 14,000-458,000/mm 3 ). The median platelet-tolymphocyte ratio was 11.27 (range 0.14-159.77). The Binet stage was A in 64.1%, B in 17.4% and C in 18.5%. The most common indications for treatment included anemia/thrombocytopenia (33%) and bulky lymph nodes (18%). During follow-up, 41% of this sample required treatment. All patients received a rituximab-based regimen 
Discussion
The CLL is a heterogeneous disease with a variable clinical course that has been historically predicted according to the Rai and Binet staging systems [7, 8] . However, they do not take into account other biological characteristics of CLL cells that may influence the disease course. To date, the advent of major molecular breakthroughs has led to the adoption of complex and expensive biomarkers such as cytogenetic abnormalities (trisomy 12, 11q deletions and 17p deletions), β2 microglobulin, thymidine kinase, CD38 and ZAP-70 expression, and IGHV mutation status, and mutations in genes such as NOTCH1, MYD88, SF3B1 and ATM are also predictors of prognosis [9] . These novel molecular advances serve the ancient hallmarks of cancer and under-recognize the current trend in the concepts of carcinogenesis [10] . Unfortunately, these new biomarkers were not performed in this retrospective series and could not be analyzed with regards to PLR. Another limitation to this analysis would be auto-immune induced thrombocytopenia that may have affected the platelet count. However, to the best of our knowledge, patients with auto-immune hematologic manifestations were not included in this analysis. Only one patient presented extreme thrombocytopenia and his work up did not reveal an immune phenomenon.
The conceptual progresses of the last decade have recognized inflammation as a major hallmark in carcinogenesis development and progression [11] . The evidence connecting inflammation and cancer is now clearly established with the description of inflammatory cytokines that affect carcinogenesis, dedifferentiation and primary tumor growth [12] . As such, several inflammatory biomarkers have been investigated for cancer prognostication [13] . Some of these factors were converted into ratios such as the Glasgow Prognostic Score, the neutrophil to lymphocyte ratio, and the PLR [5, 14] . In the particular case of PLR, its prognostic value has been confirmed in solid tumors where it was found to be correlated to OS and to cancer aggressiveness [15] . Moreover, among hematologic malignancies, PLR has only been evaluated in multiple myeloma [16] . Jung et al. have reported that the inverse PLR had a predictive value for progression-free survival and OS in the uni-and multi-variable analyses of patients with multiple myeloma treated with novel agent-containing regimens [16] .
Molica et al. have reported that the absolute count of lymphocytes doubling time was an independent prognostic factor for clinical outcomes in patients with newly diagnosed CLL. However, the prognostic role of platelet count is not well known in CLL although a low platelet count may be an indication for treatment initiation [6] . Although debatable, thrombocytopenia causes a physiologic compensatory secretion of thrombopoietin that seems to correlate with other prognostic biomarkers including IGHV mutation status, ZAP 70 and CD38 [17, 18] . Consequently, we hypothesized that the PLR is an easily adapted clinical tool that could segregate the poor prognostic patients earlier so that earlier interventions can be tested before tumor burden makes such interventions unlikely to succeed.
Conclusion & perspective
The biological rationale in calculating PLR stems from the increase in the lymphocyte count and reduction in the platelet count often encountered in the advances stages of CLL [6] . Therefore, we hypothesized that the ratio using both the platelet and lymphocyte counts may have a prognostic role in patients with CLL. The PLR correlated to the duration of watchful waiting in the univariable analysis only. In this retrospective study, some patients were not assessed for cytogenetic analysis or fluorescence in situ hybridization. Therefore, cytogenetic risk factors were not included in the uni-and multi-variable for survival outcome. These data need to be validated in a large number of patients with samples and survival data collected in a uniform fashion along with molecular analysis. We believe that a prospective study taking into consideration the methodological, physiological and pathological confounding factors should better assess the role of PLR in CLL. The PLR biomarker relates to the pathogenesis and clinical implications of CLL, which may be a surrogate for treatment indication especially in cases of cytogenetic and molecular analysis unavailability.
Executive summary

Aim
• Platelet levels tend to be decreased and lymphocyte levels are increased in patients with chronic lymphocytic leukemia (CLL).
• The rationale for platelet-to-lymphocyte ratio (PLR) as a biomarker for CLL prognosis is that these alterations in platelet and lymphocyte counts could predict the survival of patients with CLL. Methods • Demographic and clinical data of CLL patients diagnosed at our institution between 1989 and 2013 were collected.
• The duration of watchful waiting, postdiagnosis survival and postchemotherapy survival for evaluated for all patients.
• Univariable and multivariable Cox regression models were used to evaluate the role of PLR as a determinant of duration of watchful waiting, postdiagnosis survival and postchemotherapy survival.
Results
• The data of 100 patients with CLL were reviewed for this study.
• The PLR correlated only to watchful waiting in the univariable analysis (HR = 0.48 [0.32-0.73]; p = 0.018).
• In the multivariable analysis, the duration of watchful waiting was determined by Binet staging and lymphocyte count (p < 0.001).
• The postdiagnosis survival was determined by age (p = 0.002) and lymphocyte count (p = 0.010).
• The postchemotherapy survival was found to be solely determined by age (HRa = 1.13 [1.04-1.22]; p = 0.003).
• However, both postdiagnosis survival and postchemotherapy survival were not found to be related to PLR.
Conclusion
• The PLR was only found to be related to the duration of watchful waiting.
• In this study, PLR was not found to be significantly related to the survival of patients with CLL.
• The PLR does not seem to be viable biomarker for survival in patients with CLL.
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